Skip to content

13F-HR filed by Fairmount Funds Management LLC

Fairmount Funds Management LLC filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-09, with 27 holding rows worth $568,896,000.

Accession
0001104659-22-116268
Filed
2022-11-09
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2022

A holdings report, 27 entries on the cover page, a total value of $568,896,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $568,894,000 with VALUE read as thousands by filing date, 13F file number 028-19908. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AXSOME THERAPEUTICS INC. COM05464T104Stock1,896,647$84,628,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM2,758,975$41,164,000thousands by filing date
NUVALENT INC COM670703107Stock2,079,863$40,433,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock2,543,107$32,043,000thousands by filing date
BIOHAVEN PHARMACEUTICAL HOLDING11196105COM204,743$30,951,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM283,000$30,057,000thousands by filing date
INSMED INC COM PAR $.01457669307Stock1,336,368$28,785,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM1,369,623$28,091,000thousands by filing date
VERONA PHARMA PLC925050106SPONSORED ADS2,678,982$27,379,000thousands by filing date
AXSOME THERAPEUTICS INC.05464T904COM600,000$26,772,000thousands by filing datecall
ARGENX SE SPONSORED ADR04016X101ADR73,526$25,958,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM469,264$24,341,000thousands by filing date
POINT BIOPHARMA GLOBAL INC730541109COM2,833,950$21,906,000thousands by filing date
ANNEXON INC03589W102COM3,358,563$20,756,000thousands by filing date
DBV TECHNOLOGIES S A23306J101ADR7,064,964$12,505,000thousands by filing date
TYRA BIOSCIENCES INC90240B106COMMON STOCK1,416,998$12,455,000thousands by filing date
ACADIA PHARMACEUTICALS INC004225108COM751,804$12,300,000thousands by filing date
TERNS PHARMACEUTICALS INC COM880881107Stock2,050,000$12,075,000thousands by filing date
BEONE MEDICINES LTD SPONSORED ADS07725L102ADR86,400$11,648,000thousands by filing date
KEROS THERAPEUTICS INC COM492327101Stock272,498$10,251,000thousands by filing date
TREVI THERAPEUTICS INC COM89532M101Stock5,696,515$8,773,000thousands by filing date
ASTRIA THERAPEUTICS INC COM04635X102Stock911,736$8,242,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW5,584,837$6,087,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM389,588$3,732,000thousands by filing date
OLEMA PHARMACEUTICALS INC68062P106COM1,231,566$3,399,000thousands by filing date
Instil Bio, Inc.45783C101Common Stock673,905$3,262,000thousands by filing date
ALLAKOS INC01671P100COM147,189$901,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-22-116268this filing2022-11-09acceptance time not in the bulk data set